aTYR PHARMA (ATYR) risk factors

81 risks, 5 new, 6 dropped, 13 reworded since the prior year. aTyr Pharma faces new securities class action litigation and Nasdaq delisting risk as its stock traded below $1.00.

82 risks. The company faces extensive clinical trial, regulatory, and manufacturing risks as a pre-commercial biotherapeutics firm dependent on efzofitimod. There is no established FDA regulatory pathway for pulmonary sarcoidosis, threatening approval even if trials succeed. The firm relies entirely on third-party contract manufacturers and clinical research organizations.